INS and type 1 diabetes mellitus: The combination treatment was evaluated in the same two type 1 diabetes mouse models that had previously shown efficacy with aCD3 treatment [27], the virally induced RIP-LCMV-GP model, where transgenic mice express the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) under control of the rat insulin promoter (RIP) in pancreatic β-cells [30, 31], and the NOD mouse model [32].